Day One Biopharmaceuticals I (DAWN)
$17.69
+0.59
(+3.45%)▲
Insights on Day One Biopharmaceuticals I
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 53.3% return, outperforming this stock by 35.1%
Performance
- $16.67$18.06$17.69
5.76%
Downside
Day's Volatility :7.69%
Upside
2.05%
- $9.67$17.85$17.69
45.34%
Downside
52 Weeks Volatility :45.83%
Upside
0.9%
Returns
| Period | Day One Biopharmaceuticals I | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 10.39% | -1.3% | 0.0% |
6 Months | 44.43% | 12.4% | 0.0% |
1 Year | 18.18% | 4.6% | 0.0% |
3 Years | -21.38% | 15.7% | -21.9% |
Highlights
Market Capitalization | 1.2B |
Book Value | $3.97 |
Earnings Per Share (EPS) | -2.37 |
Wall Street Target Price | 36.63 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -35.52% |
Return On Equity TTM | -55.68% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -206.0M |
Diluted Eps TTM | -2.37 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.62 |
EPS Estimate Next Year | -1.91 |
EPS Estimate Current Quarter | -0.58 |
EPS Estimate Next Quarter | -0.6 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 107.07%
Technicals Summary
Sell
Neutral
Buy
Day One Biopharmaceuticals I is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Day One Biopharmaceuticals I | 5.82% | 44.43% | 18.18% | -21.38% | -21.38% |
 Moderna, Inc. | 4.46% | 44.76% | -17.31% | -40.7% | 317.84% |
 Regeneron Pharmaceuticals, Inc. | -8.11% | 12.56% | 10.41% | 82.28% | 161.35% |
 Novo Nordisk A/s | 0.6% | 31.36% | 53.28% | 240.62% | 422.33% |
 Vertex Pharmaceuticals Incorporated | -6.58% | 6.36% | 13.86% | 80.23% | 127.58% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Day One Biopharmaceuticals I | 3.54 | NA | NA | -2.62 | -0.56 | -0.36 | NA | 3.97 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 26.04 | 26.04 | 1.46 | 45.0 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.43 | 47.43 | 2.4 | 3.35 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.75 | 0.23 | 0.13 | NA | 68.22 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Day One Biopharmaceuticals I | Buy | $1.2B | -21.38% | 3.54 | 0.0% |
Moderna, Inc. | Buy | $41.7B | 317.84% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $99.5B | 161.35% | 26.04 | 30.14% |
Novo Nordisk A/s | Buy | $562.8B | 422.33% | 47.43 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.6B | 127.58% | 28.81 | 36.68% |
Institutional Holdings
RA Capital Management, LLC
8.94%BlackRock Inc
5.87%Vanguard Group Inc
5.46%Goldman Sachs Group Inc
4.85%Franklin Resources Inc
4.85%FMR Inc
4.54%
Company Information
day one biopharmaceuticals understands that advances in cancer research now enable drug developers to identify children and adults who may benefit from the same medicine. we are a unique company created to find and develop new therapies that meet the critical needs of people of all ages living with cancer – starting from the biology of childhood cancer. our distinctive approach, together with our trusted network of pediatric oncology investigators, gives us an unparalleled ability to advance promising discoveries for patients of any age. we are ready to pursue the full potential of our therapies to improve the greatest number of lives as quickly as possible.
Organization | Day One Biopharmaceuticals I |
Employees | 155 |
CEO | Dr. Jeremy Bender M.B.A., Ph.D. |
Industry | Healthcare |
